A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...